Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD


Primary and secondary lung function endpoints met

Read the original here:
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Related Posts